Valeant Pharmaceuticals International from Canada and PharmaSwiss S.A. from Switzerland have signed a preliminary agreement on the acquisition of PharmaSwiss S.A.
Supported by
PharmaSwiss S.A. produces generic drugs, which it sells under its name, and non-prescription drugs. Valeant is to pay €350 million for the acquisition.
Supported by
After the sales contract is concluded, PharmaSwiss will have about €38 million in cash and no debt.
Source Ekapija.com
Supported by
Supported by
